TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17597387

Group type: EXPERIMENTAL
Intervention: Genetics education module provided by Reach to Recovery peer volunteers
Number of subjects: 113

Group type: COMPARATOR
Intervention: No genetics education module
Number of subjects: 113
Study: 15536601

Group type: EXPERIMENTAL
Intervention: Glyburide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pharmacologic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population comparisons (non-obese vs obese)
Number of subjects: 0
Study: 11559654

Group type: EXPERIMENTAL
Intervention: olsalazine 2.0 g daily for 52 weeks
Number of subjects: 328

Group type: COMPARATOR
Intervention: placebo for 52 weeks
Number of subjects: 328
Study: 9211442

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 36
Study: 8290432

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 12
Study: 3721903

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented milk formula
Number of subjects: 84

Group type: COMPARATOR
Intervention: Milk formula
Number of subjects: 84

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 84
Study: 2527533

Group type: EXPERIMENTAL
Intervention: Cilazapril (0.5 to 5 mg dose range)
Number of subjects: 24
Study: 31122027

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 176

Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 176
Study: 30740640

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 95
Study: 28619118

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HMW-APN (high molecular weight adiponectin)
Number of subjects: 120
Study: 24996117

Group type: EXPERIMENTAL
Intervention: 10-week home-based exercise programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Practice as usual
Number of subjects: 142
Study: 22484418

Group type: EXPERIMENTAL
Intervention: Extramedullary (EM) femoral alignment system
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intramedullary (IM) femoral alignment system
Number of subjects: 91
Study: 21344327

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (amoxicillin and metronidazole) in combination with non-surgical subgingival debridement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical subgingival debridement
Number of subjects: 0
Study: 19298641

Group type: EXPERIMENTAL
Intervention: i.v. paricalcitol (0.04 ug/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: i.v. calcitriol (0.01 ug/kg)
Number of subjects: 25
Study: 16403695

Group type: EXPERIMENTAL
Intervention: 10-session cognitive behaviour therapy-based group intervention
Number of subjects: 33
Study: 12808136

Group type: EXPERIMENTAL
Intervention: Insulin (1.5 milliunits/kg of fat‐free mass per min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin (low to high levels)
Number of subjects: 0
Study: 10702462

Group type: EXPERIMENTAL
Intervention: Remifentanil (50 microg/mL) by syringe from an infusion pump
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil 20 microg/mL through a minidrip set
Number of subjects: 40
Study: 9112968

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin type A (BtA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 14
Study: 7968331

Group type: EXPERIMENTAL
Intervention: 3 mL 2% lidocaine intrathecally (Group A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mL 2% lidocaine epidurally (Group B)
Number of subjects: 12
Study: 3707671

Group type: EXPERIMENTAL
Intervention: bezafibrate (600 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: diet plus bezafibrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: diet plus placebo
Number of subjects: 12
Study: 29395407

Group type: EXPERIMENTAL
Intervention: Live music therapy session after wound care in addition to standard care
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Live music therapy for children older than 5 years
Number of subjects: 135
Study: 27484456

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left inferior frontal gyrus (1 mA, 20 minutes)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham-tDCS over the left inferior frontal gyrus
Number of subjects: 58
Study: 23574660

Group type: EXPERIMENTAL
Intervention: GP plus workplace health advisers
Number of subjects: 60

Group type: COMPARATOR
Intervention: GP alone
Number of subjects: 60
Study: 23762840

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IFRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective nodal irradiation (ENI)
Number of subjects: 0
Study: 21223769

Group type: EXPERIMENTAL
Intervention: Endometrial stimulation
Number of subjects: 759

Group type: COMPARATOR
Intervention: Control (no endometrial stimulation)
Number of subjects: 759
Study: 17922535

Group type: EXPERIMENTAL
Intervention: Prodieting message
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Antidieting message
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 139
Study: 15917007

Group type: EXPERIMENTAL
Intervention: Special Training Condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard Training Condition
Number of subjects: 15
Study: 12174057

Group type: EXPERIMENTAL
Intervention: 2% fluridil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fluridil (former placebo subjects)
Number of subjects: 43
Study: 9640121

Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 4 micrograms.ml‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 6 micrograms.ml‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nitrous oxide 67% in oxygen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Technique using nitrous oxide supplemented with alfentanil
Number of subjects: 40
Study: 7658266

Group type: EXPERIMENTAL
Intervention: Nasal prongs
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nasopharyngeal catheter
Number of subjects: 118
Study: 2748931

Group type: EXPERIMENTAL
Intervention: High prescribed tempo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low prescribed tempo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preferred tempo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Increasing tempo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Discovery learning (no prescribed tempo)
Number of subjects: 75
Study: 773736

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diphenoxylate
Number of subjects: 23
Study: 31664751

Group type: EXPERIMENTAL
Intervention: 3% TA combination serum (3% TA, 4% galactomyces ferment filtrate, 2% niacinamide, and 4% alpha arbutin)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2% TA combination serum
Number of subjects: 44

Group type: COMPARATOR
Intervention: 4% hydroquinone
Number of subjects: 44
Study: 30011836

Group type: EXPERIMENTAL
Intervention: Whey peptide
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 26176261

Group type: EXPERIMENTAL
Intervention: 2D schedule (M0,6)
Number of subjects: 240

Group type: COMPARATOR
Intervention: 3D schedule (M0,1,6)
Number of subjects: 240
Study: 24974994

Group type: EXPERIMENTAL
Intervention: Temporary Anchorage Devices (TADs)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nance button palatal arches
Number of subjects: 78

Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 78
Study: 22257645

Group type: EXPERIMENTAL
Intervention: DHEA + COC (oral micronized DHEA 50 mg + 20 µg ethinyl estradiol/0.1 mg levonorgestrel combined oral contraceptive pill daily; n = 43)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: DHEA + COC
Number of subjects: 94
Study: 18502689

Group type: EXPERIMENTAL
Intervention: Informative video
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 93
Study: 17448045

Group type: EXPERIMENTAL
Intervention: Speed brackets (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GAC brackets (G)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 16
Study: 14752639

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (ABP)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 974
Study: 12002922

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg IV
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg IV
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9653594

Group type: EXPERIMENTAL
Intervention: Glimepiride plus insulin (GI)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo plus insulin (PI)
Number of subjects: 145
Study: 8582105

Group type: COMPARATOR
Intervention: Low level counselling (one practice appointment and five telephone counselling appointments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High level counselling (six appointments in general practice)
Number of subjects: 0
Study: 2708607

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment combined with response prevention of vomiting
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 77
Study: 797215

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 16
Study: 31038717

Group type: EXPERIMENTAL
Intervention: Upper limb exercise
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Breathing exercise
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 29057266

Group type: EXPERIMENTAL
Intervention: Tapered double-lead threads single implants placed at the time of tooth extraction (TG)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tapered double-lead threads single implants placed 3 months after extraction (CG)
Number of subjects: 92
Study: 25597411

Group type: EXPERIMENTAL
Intervention: Lifestyle change plus dental care (LCDC) program
Number of subjects: 132

Group type: COMPARATOR
Intervention: Routine program (control)
Number of subjects: 132
Study: 23378222

Group type: EXPERIMENTAL
Intervention: Exposure to sexual visual cues ON dopamine medication
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exposure to sexual visual cues OFF dopamine medication
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (Parkinson's disease patients without hypersexuality)
Number of subjects: 12
Study: 20033250

Group type: EXPERIMENTAL
Intervention: Introductory exemplary questions before completing the SF-36 questionnaire
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standardized SF-36 imputation algorithm
Number of subjects: 215
Study: 19477891

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily for 14 days)
Number of subjects: 4372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 4372
Study: 17761995

Group type: EXPERIMENTAL
Intervention: Invited for screening for type 2 diabetes
Number of subjects: 7380

Group type: COMPARATOR
Intervention: Not invited (controls)
Number of subjects: 7380
Study: 15188323

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (lecture, audit, reminder mailing)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group (no special education)
Number of subjects: 373
Study: 11440560

Group type: COMPARATOR
Intervention: Placebo antitussive syrup (60 ml)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated state
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 22
Study: 9130756

Group type: EXPERIMENTAL
Intervention: PN group (embryos cryopreserved at the pronucleate stage)
Number of subjects: 364

Group type: COMPARATOR
Intervention: EC group (embryos frozen at the 2- to 4-cell stage)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: PN group (thawed embryos)
Number of subjects: 364

Group type: COMPARATOR
Intervention: EC group (thawed embryos)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: PN group
Number of subjects: 364

Group type: COMPARATOR
Intervention: EC group
Number of subjects: 364
Study: 1958435

Group type: EXPERIMENTAL
Intervention: UK-68,798 (5 micrograms kg-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: UK-68,798 (10 micrograms kg-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6129752

Group type: EXPERIMENTAL
Intervention: beta-receptor blockers (talinolol and propranolol)
Number of subjects: 118
Study: 31928846

Group type: EXPERIMENTAL
Intervention: Group A (56 subjects) with cognitive and structural variables compared between converters and nonconverters.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Group B (57 subjects) with cognitive and structural variables compared to Group A.
Number of subjects: 113
Study: 31474148

Group type: EXPERIMENTAL
Intervention: Suprapatellar approach
Number of subjects: 95

Group type: COMPARATOR
Intervention: Infrapatellar approach
Number of subjects: 95
Study: 29044556

Group type: EXPERIMENTAL
Intervention: Play-based intervention
Number of subjects: 26
Study: 26027450

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance training
Number of subjects: 54
Study: 24548129

Group type: EXPERIMENTAL
Intervention: Pregnenolone (50 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23217477

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Number of subjects: 60
Study: 20382445

Group type: EXPERIMENTAL
Intervention: Intravenous 0.15 μg/kg sufentanil, followed by 0.075 μg/kg every 3 minutes
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous 0.15 mg/kg morphine, followed by 0.075 mg/kg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups experienced adverse events
Number of subjects: 108
Study: 18650074

Group type: EXPERIMENTAL
Intervention: Wavelet transform‐complex‐valued artificial neural network (WT‐CVANN)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Complex wavelet transform‐complex‐valued artificial neural network (CWT‐CVANN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Real-valued artificial neural network (RVANN)
Number of subjects: 78
Study: 15997043

Group type: EXPERIMENTAL
Intervention: Multidisciplinary specialized outpatient clinic care
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 230
Study: 12709777

Group type: EXPERIMENTAL
Intervention: 20 mg LY354740
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 200 mg LY354740
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10498345

Group type: EXPERIMENTAL
Intervention: 200 IU/day of nasal spray of salmon calcitonin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8732311

Group type: EXPERIMENTAL
Intervention: triprolidine-D
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: astemizole-D
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 1403034

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg four times per day and hydrocortisone 20 mg twice per day
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 4002791

Group type: EXPERIMENTAL
Intervention: 40 mg muzolimine after a standardized breakfast with 1760 mg aluminium hydroxide administered 10 min before breakfast
Number of subjects: 6

Group type: COMPARATOR
Intervention: 40 mg muzolimine after a standardized breakfast without aluminium hydroxide
Number of subjects: 6
Study: 30681351

Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 8

Group type: COMPARATOR
Intervention: 21% O2 (room air)
Number of subjects: 8
Study: 29882333

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27852385

Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules + furazolidone-based triple therapy (group A1)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules + furazolidone-based quadruple therapy (group A2)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Bismuth potassium citrate + furazolidone-based triple therapy (group B1)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate + furazolidone-based quadruple therapy (group B2)
Number of subjects: 357
Study: 25134294

Group type: EXPERIMENTAL
Intervention: Foley catheter tourniquet around both uterine vessels (Group 1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No tourniquet (Control Group 2)
Number of subjects: 67
Study: 23173249

Group type: EXPERIMENTAL
Intervention: qi supplementing, collateral dredging, detoxifying, and turbidity descending recipe (QSCDDTDR) combined with basic methods of Western medicine (WM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: niaoduqing granule (NDQG)
Number of subjects: 160
Study: 20351374

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied at LU6, LI4, ST36 and ST6 for 30 min after exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control treatment (rest without acupuncture)
Number of subjects: 12
Study: 18056557

Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) plus an attention control for parents (Goal for It [GFI])
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Wonderous Wetlands (WW) plus the GFI
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: CImPACT (for parents)
Number of subjects: 1282
Study: 16043810

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with varying duty-cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard duty-cycles of VNS
Number of subjects: 0
Study: 12170403

Group type: EXPERIMENTAL
Intervention: Group E (pronase, sodium bicarbonate, and DMPS plus water)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group C (pronase only with water)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Group D (pronase and sodium bicarbonate plus water)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Group A (DMPS alone)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Group B (DMPS plus water)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CLO test results
Number of subjects: 160
Study: 10444932

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (CE MRA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 23
Study: 7480918

Group type: EXPERIMENTAL
Intervention: Oral levamisole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixture of alive BCG plus autoclaved M. leprae
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mitsuda antigen retesting
Number of subjects: 20
Study: 2340610

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg.kg‐1), fentanyl (1 microgram.kg‐1), propofol (2 mg.kg‐1), succinylcholine (1 mg.kg‐1), anaesthesia maintained with propofol (6 mg.kg‐1.hr‐1), N2O (67 per cent), O2 (33 per cent)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Thiopentone (4 mg.kg‐1), anaesthesia maintained with N2O (67 per cent), O2 (33 per cent), enflurane (0.5 per cent inspired concentration)
Number of subjects: 19
Study: 6767648

Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride (Adrevil forte) 3 x 2 tablets daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride (Adrevil forte)
Number of subjects: 32
Study: 31498394

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 60
Study: 31425552

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Demographics (age and gender)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: History of dispensing
Number of subjects: 1000
Study: 27878873

Group type: EXPERIMENTAL
Intervention: Spaced retrieval training for hyperphagia behavior (6-week duration)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Spaced retrieval training
Number of subjects: 97
Study: 24956415

Group type: EXPERIMENTAL
Intervention: DASH diet for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control diet for 8 weeks
Number of subjects: 48
Study: 23422925

Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 13 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 13 days in MDR1 3435 TT individuals
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 13 days in MDR1 3435 CT individuals
Number of subjects: 18
Study: 22027785

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Benazepril 10 mg/day
Number of subjects: 60
Study: 19427431

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 6632

Group type: COMPARATOR
Intervention: No history of hypertension
Number of subjects: 6632

Group type: EXPERIMENTAL
Intervention: History of hypertension (in patients without previous HF)
Number of subjects: 6632

Group type: EXPERIMENTAL
Intervention: History of hypertension (in patients with previous HF)
Number of subjects: 6632
Study: 17978327

Group type: EXPERIMENTAL
Intervention: Training staff in community mental health teams to deliver substance misuse interventions
Number of subjects: 13
Study: 15308911

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine infusion (20 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no morphine)
Number of subjects: 50